Copyright © 2024 Springer Healthcare Limited. Part of the Springer Nature Group.
CH_EM-115759
ASCO Direct™ GU Highlights Meeting 2024
Update in Genitourinary Cancers
February 2, 2024 | Zürich, Switzerland & Virtual
Welcome
Many thanks to everyone, who attended the hybrid ASCO Direct™ GU Highlights Meeting on Friday, February 2, 2024.
The ASCO Direct™ GU Highlights Meeting was an educational program containing selected original sessions from the 2024 ASCO Genitourinary Cancers Symposium on prostate, renal cell and urothelial cancer. Attendees had the opportunity to view the original sessions and discuss the clinical relevance and implications for Swiss treatment landscape of study outcomes with their colleagues.
Here are the program and details of the ASCO Direct™ GU Highlights Meeting 2024. We look forward to organizing the ASCO Direct™ GU Highlights meeting 2025. The related information will be available later this year.
If you would like any further information, please feel free to contact us at asco@springer.com
Prof. Dr. med. Jörg Beyer and PD Dr. med. Aurelius Omlin
Benefits of the meeting
- Easy and timesaving option to keep informed about the latest news and developments in GU cancers
- Discussion with Swiss experts and colleagues
- Selection of presentations from the 2024 ASCO GU Symposium that are most clinically-relevant for Switzerland
- On-demand access to all videos, slides and posters from the 2024 ASCO GU Symposium via ASCO’s site
- CME credits (for live attendees)
On-demand recordings
The on-demand recordings are no longer available.
Scientific committee
The program is supervised by an independent scientific committee:
- Prof. Dr. med. Jörg Beyer – Inselspital Bern
- PD Dr. med. Aurelius Omlin – Onkozentrum Zürich
GU Cancer Experts:
- Dr. med. Alexandros Papachristofilou – Universitätsspital Basel
- PD Dr. med. Thomas Hermanns – Hirslanden Zürich
- PD Dr. med. Ursula Vogl – Ente Ospedaliero Cantonale Bellinzona
- Dr. med. Katharina Hoppe – Stadtspital Triemli
- Prof. Dr. med. Anja Lorch – Universitätsspital Zürich
- PD Dr. med. Christian Fankhauser – Luzerner Kantonsspital
Program
Friday, February 2, 2024, from 14:30 until 19:30
14:30–14:35
Introduction
Jörg Beyer, Aurelius Omlin
14:35–16:00
Prostate Session
Aurelius Omlin, Alexandros Papachristofilou, Thomas Hermanns, Jonathan Hollmann
- Thomas Hermanns – Introduction
- Scott E. Eggener – Abstract 262: Stockholm3 validation in a multi-ethnic cohort for prostate cancer (SEPTA) detection: A multicentered, prospective trial.
- Alexandros Papachristofilou – Introduction
- Christophe Hennequin – Abstract LBA 259: Long-term results of dose escalation (80 vs 70 Gy) combined with long-term androgen deprivation in high-risk prostate cancers: GETUG-AFU 18 randomized trial.
- Aurelius Omlin – Introduction
- Neeraj Agarwal – Abstract 18: CONTACT-2: Phase 3 study of cabozantinib (C) plus atezolizumab (A) vs second novel hormonal therapy (NHT) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).
16:15–17:45
Renal Cell Carcinoma
Ursula Vogl, Katharina Hoppe, Sara Merler
- Ursula Vogl – Introduction
- Robert Motzer – Abstract LBA 358: Adjuvant nivolumab monotherapy vs placebo for localized renal cell carcinoma at high risk of relapse after nephrectomy: Results from Part B of the randomized, phase 3 CheckMate 914 trial.
- Toni Choueiri – Abstract LBA359: Overall survival results from the phase 3 KEYNOTE-564 study of adjuvant pembrolizumab versus placebo for the treatment of clear cell renal cell carcinoma (ccRCC).
- Katharina Hoppe – Introduction
- Maria Teresa Bourlon – Abstract: 362: Nivolumab plus cabozantinib (N+C) vs sunitinib (S) for previously untreated advanced renal cell carcinoma (aRCC): Results from 55-month follow-up of the CheckMate 9ER trial.
- Nizar M. Tannir – Abstract 363: Nivolumab plus ipilimumab (NIVO+IPI) vs sunitinib (SUN) for first-line treatment of advanced renal cell carcinoma (aRCC): Long-term follow-up data from the phase 3 CheckMate 214 trial.
18:00–19:25
Urothelial Carcinoma
Anja Lorch, Christian Fankhauser, Fabian Aschwanden
- Christian Fankhauser – Introduction
- Matthew Nicholas Young – Abstract 534: Predictive value of dynamic changes in ctDNA and baseline biomarkers with neoadjuvant atezolizumab in operable urothelial carcinoma in the ABACUS trial.
- Andrea B. Apolo – Abstract LBA 531: AMBASSADOR Alliance A031501: Phase III randomized adjuvant study of pembrolizumab in muscle-invasive and locally advanced urothelial carcinoma (MIUC) vs observation.
- Anja Lorch – Introduction
- Michiel Simon Van Der Hejiden – Abstract LBA 530: Enfortumab vedotin (EV) in combination with pembrolizumab (P) versus chemotherapy in previously untreated locally advanced metastatic urothelial carcinoma (la/mUC): Subgroup analyses results from EV-302, a phase 3 global study.
- Rohit K. Jain – Abstract 539: Cabozantinib plus pembrolizumab as first-line therapy for cisplatin-ineligible advanced urothelial carcinoma (PemCab)
19:25–19:30
Closing Remarks
Jörg Beyer, Aurelius Omlin
CME credits
The meeting is CME accredited for the live participation (in person as well as virtual).
The on-demand version (recording of the meeting) is not CME accredited.
Location
AMERON Zürich Bellerive au Lac
Utoquai 47
8008 Zürich
Venue website: https://ameroncollection.com/en/zuerich-bellerive-au-lac
Sponsors
Main sponsor
Gold sponsors
Silver sponsors
ASCO disclaimer
ASCO Direct™ is an officially licensed program of the American Society of Clinical Oncology®. ASCO® is a registered trademark of the American Society of Clinical Oncology. All rights reserved. ASCO does not endorse any health care product, therapy, diagnostic test or device.